Sutro Biopharma to Participate in Four Upcoming Investor Conferences
Sutro Biopharma (NASDAQ: STRO) announced CEO Bill Newell's participation in four virtual conferences scheduled from November to December 2020. Key details include:
- Stifel Virtual Healthcare Conference: Nov. 16, at 3:20 PM ET.
- Jefferies Virtual London Healthcare Conference: Nov. 19, at 12:35 PM ET.
- Piper Sandler 32nd Annual Healthcare Conference: Dec. 1-3, with discussions available from Nov. 23.
- Evercore ISI HealthCONx Conference: Dec. 3, at 10:30 AM ET.
Webcasts will be available through the company’s Investor Relations website.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences in November and December of 2020.
Presentations Details:
2020 Stifel Virtual Healthcare Conference
Format: Corporate Presentation
Date: Monday, Nov. 16, 2020
Time: 3:20pm ET / 12:20pm PT
Jefferies Virtual London Healthcare Conference
Format: Virtual Fireside Chat
Date: Thursday, Nov. 19, 2020
Time: 12:35pm ET / 9:35am PT / 5:35pm GMT
Piper Sandler 32nd Annual Healthcare Conference
Format: Virtual Fireside Chat
Date: Tuesday, Dec. 1-3, 2020
Note: Fireside Discussion Available Nov. 23 through Dec. 3
3rd Annual Evercore ISI HealthCONx Conference
Format: Virtual Fireside Chat
Date: Thursday, Dec. 3, 2020
Time: 10:30am ET / 7:30am PT
Live webcasts of each presentation can be accessed through the Events and Presentations page of the Investor Relations section on the company's website at www.sutrobio.com. Archived replays of the webcasts will be available on the company's website for approximately 30 days following each live presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro's first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, including multiple myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha (FolRα)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers. This is the second product candidate to be evaluated in clinical trials resulting from Sutro's XpressCF® and XpressCF+™ technology platforms. A third program, CC-99712 (BCMA-targeting ADC), which is part of Sutro's collaboration with Bristol Myers Squibb (formerly Celgene Corporation), is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma. Sutro's proprietary technology was responsible for the discovery and manufacturing of CC-99712, for which Bristol Myers Squibb has worldwide development and commercialization rights. Sutro is entitled to development and regulatory milestone payments and tiered royalties from Bristol Myers Squibb for this BCMA ADC. Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.
Additional multimedia content from Sutro regarding STRO-001 and STRO-002 can be found here and here.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of clinical trials and announcements of clinical results, potential benefits of the company's product candidates and platform and potential market opportunities for the company's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the impact of the COVID-19 pandemic on the Company's business, clinical trial sites, supply chain and manufacturing facilities, the Company's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical studies and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property, and the Company's commercial collaborations with third parties and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Investor Contacts
Annie Chang
Sutro Biopharma, Inc.
(650) 801-5728
ajchang@sutrobio.com
Media Contacts
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
View original content:http://www.prnewswire.com/news-releases/sutro-biopharma-to-participate-in-four-upcoming-investor-conferences-301170774.html
SOURCE Sutro Biopharma
FAQ
What are the details of Sutro Biopharma's upcoming virtual conferences in November and December 2020?
Who will represent Sutro Biopharma at the upcoming investor conferences?
How can I access the webcasts of Sutro Biopharma's presentations?
What products is Sutro Biopharma currently developing?
When was the Orphan Drug Designation for STRO-001 granted by the FDA?
